Society for Immunotherapy of Cancer Unveils Late-Breaking Abstracts and Press Briefing Lineup for SITC 2026

The Society for Immunotherapy of Cancer (SITC) has announced the titles and authors of its accepted late-breaking abstracts for the upcoming 41st Annual Meeting & Pre-Conference Programs. Following a submission pool of nearly 1,200 abstracts in 2026, the organization selected key interventional clinical trial data highlighting emerging advances in tumor immunology and immunotherapy research.

The meeting is scheduled to take place from November 4 to 8, 2026, in Phoenix, Arizona, with a virtual attendance option available. Additionally, SITC will host a virtual press briefing on Wednesday, November 4, 2026, from 12:00 p.m. to 1:30 p.m. Mountain Time to showcase selected top advances.

Featured Late-Breaking Presentations

The press briefing lineup features several notable clinical trials and studies spanning various cancer types and therapeutic approaches:

• Abstract #553: Interim report of an ongoing Phase II clinical trial on the adoptive transfer of T cells engineered with mutant p53-specific TCRs for metastatic solid epithelial cancers, presented by Sanghyun Kim, PhD (National Cancer Institute).
• Abstract #323: Research examining adaptive anti-CAR immunity and its impact on the durability of GD2-CAR T cell therapy in diffuse midline glioma, presented by Kevin Reynolds, MD (Stanford Cancer Institute).
• Abstract #566: Pooled safety and updated efficacy data for OBX-115 TIL cell therapy in immune checkpoint inhibitor-resistant advanced melanoma, presented by Rodabe Amaria, MD (The University of Texas MD Anderson Cancer Center).
• Abstract #1176: Findings on adoptive immunotherapy with effector T lymphocytes generated after cancer neoantigen vaccination in MGMT unmethylated glioblastoma multiforme patients, presented by Patrick Grogan, MD (Moffitt Cancer Center).
• Abstract #828: Data on oncolytic adenoviruses inducing tertiary lymphoid structures in brain tumors, presented by Hong Jiang, PhD (The University of Texas MD Anderson Cancer Center).
• Abstract #501: A Phase 1b trial investigating intratumoral administration of the seasonal influenza vaccine in melanoma patients, presented by Ian Garbarine, MD (The Ohio State University Comprehensive Cancer Center).
• Abstract #1182: A Phase 1/1b study evaluating the tumor-activated IL-2 prodrug WTX-124, alone or combined with pembrolizumab, in advanced solid tumors, presented by Justin Moser, MD (HonorHealth Research Institute).
• Abstract #1185: Results from global, multicenter Phase 1/2 studies assessing the safety and efficacy of cesalatamig, a novel PD-1/VEGF bispecific antibody, in PD-(L)1-resistant non-small cell lung cancer, presented by Kai He, MD, PhD (University of Texas Mays Cancer Center at San Antonio).

Practical Implications and Verification

The disclosures provide a transparent look into active clinical pathways within oncology research, offering medical professionals and industry observers a preview of upcoming data releases. Certain data shared during the press briefing may be subject to embargoes lasting until specific presentations occur during the broader annual meeting.

Readers and accredited media representatives can verify the complete announcement, review the official media policy, and check registration details directly through the [PR Newswire Official Source](https://www.prnewswire.com/news-releases/the-society-for-immunotherapy-of-cancer-announces-late-breaking-abstracts-and-press-briefing-presented-at-sitc-2026-302923852.html). Press accreditation guidelines and session timings are managed through the official [SITC 2026 Annual Meeting Website](http://www.sitcancer.org/2026).